Henderson Mary Elizabeth's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Mar 2, 2026
- Accession no.
- 0001989533-26-000006
- Filed
- Mar 2, 2026
- Trade date
- Feb 26, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $1.04M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Henderson Mary ElizabethCIK 0001989533 | Officer (SVP, Technical Operations) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Ordinary Shares | AGrant or awardAcquired | +4,447 | $0.00 | $0 | 34,071 | Direct | |
| Feb 26, 2026 | Ordinary Shares | SSaleDisposed | −5,343 | $194.49F3 | −$1,039,160.07 | 28,728 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $194.1900 to $194.5000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.